Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) shares traded up 4.2% during mid-day trading on Tuesday. The stock traded as high as $107.68 and last traded at $111.9820. 283,857 shares changed hands during trading, a decline of 67% from the average session volume of 851,678 shares. The stock had previously closed at $107.48.
Analyst Ratings Changes
Several equities analysts have commented on the company. Needham & Company LLC lowered their price target on Rhythm Pharmaceuticals from $130.00 to $114.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. Canaccord Genuity Group set a $154.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Deutsche Bank assumed coverage on shares of Rhythm Pharmaceuticals in a report on Friday, August 28th. They set a "hold" rating and a $120.00 price objective for the company. Leerink Partners started coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, September 14th. They issued an "outperform" rating and a $133.00 target price on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, October 15th. Eighteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $142.00.
Get Our Latest Analysis on RYTM
Rhythm Pharmaceuticals Price Performance
The company has a market capitalization of $8.01 billion, a price-to-earnings ratio of -40.04 and a beta of 2.17. The business has a fifty day moving average price of $96.98 and a 200 day moving average price of $97.46.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.61) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.10. The business had revenue of $92.13 million during the quarter, compared to analyst estimates of $85.56 million. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 171.16%. The firm's revenue for the quarter was up 79.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.82) earnings per share. As a group, sell-side analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.90 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Rhythm Pharmaceuticals news, CFO Hunter Smith sold 62,774 shares of Rhythm Pharmaceuticals stock in a transaction on Monday, August 31st. The shares were sold at an average price of $105.46, for a total transaction of $6,620,146.04. Following the completion of the sale, the chief financial officer owned 114,024 shares of the company's stock, valued at approximately $12,024,971.04. The trade was a 35.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Meeker sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the completion of the sale, the chief executive officer directly owned 239,258 shares of the company's stock, valued at $24,564,618.86. The trade was a 17.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.90% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Rhythm Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at about $683,601,000. Primecap Management Co. CA purchased a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at $351,838,000. Checkpoint Capital L.P. boosted its holdings in shares of Rhythm Pharmaceuticals by 2.6% in the 3rd quarter. Checkpoint Capital L.P. now owns 1,216,574 shares of the company's stock worth $115,836,000 after buying an additional 30,574 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Rhythm Pharmaceuticals by 2.0% during the third quarter. Pictet Asset Management Holding SA now owns 976,487 shares of the company's stock worth $93,019,000 after purchasing an additional 18,702 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in Rhythm Pharmaceuticals during the 2nd quarter worth about $102,752,000.
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.